Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. (FRX.TO) Revenue
Annual & quarterly revenue history · segment & region breakdown
FRX.TO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsFennec Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.05B, a decrease of 4.45% year-over-year from $0.05B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.05B | -$0.00B | -4.45% |
| 2024-12-31 | $0.05B | +$0.03B | +123.69% |
| 2023-12-31 | $0.02B | +$0.02B | +1284.50% |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | -$0.00B | -100.00% |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Fennec Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Fennec Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Fennec Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
FRX.TO revenue · 4 questionsFRX.TO's trailing twelve-month (TTM) revenue is $0.05B. That is a decrease of 4.45% year-over-year from $0.05B in FY2025.
▸ Source: FMP · Fennec Pharmaceuticals Inc. SEC filings · GAAP · Fennec Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026